Carbapenems: A literature Review regarding Resistance, Risk Factors, and Mortality in Pneumonia
Abstract
Carbapenem is one of antibiotic to treat respiratory infections such as pneumonia that frequently used in tertiary care facilities and started to create resistances. This study aims to review the resistance of carbapenems, assess the risk factors for resistance that leads to mortality, and the more effective antibiotic treatment options to overcome the resistance. Assessment of the use of carbapenems in pneumonia through previous studies were carried out by searching the articles in search engine databases in 2011 to 2021. Articles reporting carbapenems resistance, risk factors, and mortality were selected based on inclusion and exclusion criteria. Of 14 articles included in inclusion criteria, 4 studies reported the occurrence of resistance to gram-negative bacteria such as Acinetobacter aumanii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, and 10 articles reported risk factors and mortality. The risk factors for carbapenems resistance are the history of carbapenems use, duration of hospitalization, use of mechanical ventilation, high Simplified Acute Physiology Score (SAPS) scores, and high Acute Physiologic and Chronic Health Evaluation (APACHE). Carbapenems resistance causes mortality such as septic shock, high Sequential Organ Failure Assessment (SOFA) scores, and elevated risk at > 60 years of age, female sex, and inappropriate choice of antibiotics. The results showed that imipenem has higher resistance than other carbapenems members, the risk factors for carbapenems resistance are dominated by a history of carbapenems use, mortality caused by high score SOFA, and colistin can be the current choice to overcome carbapenems resistance.
Keywords
Full Text:
PDFReferences
World Health Organization. (2019). Pneumonia. https://www.who.int/news-room/fact-sheets/detail/pneumonia accesessed on 16 February 2021.
Cilloniz, C. et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for streptococcus pneumoniae. American Journal of Respiratory and Critical Care Medicine. 2015; 191, 1265–1272.
Mandell, L. A. Community-acquired pneumonia: An overview. Postgraduate Medical Journal.2015; 127, 607–615
UNICEF. Every Child ’s Right To Survive : An Agenda To End Pneumonia Deaths. (2020). accessed on 16 February 2021.
McAllister, D. A. et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Global Health.2019;7, e47–e57.
WHO. The Top 10 causes of Death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (2016).
Kementrian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia Tahun 2019. (2020).
Handy, L. K., Bryan, M. & Gerber, J. S. Variability in Antibiotic Prescribing for Community-Acquired Pneumonia. Pediatrics.2017 Apr;139(4):e20162331
Leung, A. K. C., Wong, A. H. C. & Hon, K. L. Community-Acquired Pneumonia in Children. Recent Patents on Inflammation and Allergy Drug Discovery. 2018;12(2):136-144
Metlay, J. P. et al. Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine. 2019 Oct 1;200(7):e45-e67.
Mathur, S., Fuchs, A., Bielicki, J., Van Den Anker, J. & Sharland, M. Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review. Paediatrics and International Child Health. 2018 Nov;38(sup1):S66-S75 38, S66–S75 (2018).
Morehead, M. S. & Scarbrough, C. Emergence of Global Antibiotic Resistance. Primary Care: Clinics in Office Practice. 2018 Sep;45(3):467-484
Ito, M., Kaneko, Takashi., Goto, Hideto., et al. Clinical efficacy of carbapenems on hospital-acquired pneumonia in accordance with the Japanese Respiratory Society Guidelines for management of HAP. The Journal Of Infection and Chemotherapy. 2011 Dec;17(6):770-5.
Qu, X,. et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae in Chinese hospitals - A five-year retrospective study. Journal of Infection in Developing Countries. 2019 Dec 31;13(12):1101-1107.
Lemos, E. V. F.P de La Hoz et al. Carbapenem resitance and mortality in patients with Acinetobacter baumannii infection: Systematic review and meta-analysis. Clinical Microbiology and Infection. 2014 May;20(5):416-23.
Mi, X., Li, Wenrui., et al. The drug use to treat community-acquired pneumonia in children: A cross-sectional study in China. Medical Journal. 2018 Nov;97(46):e13224.
Okumura, J., Yuichiro, Shindo, et al. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy. Respirology. 2018 May;23(5):526-534.
Teng, S. O. et al. Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: Impact on empiric therapy and antibiotic resistance. Journal of. Microbiology and Immunoogy. Infection. 2015 Oct;48(5):525-30.
Karakuzu, Z. et al. Prognostic risk factors in ventilator-associated pneumonia. Medical. Science Monitor. 2018 Mar 5;24:1321-1328.
Llor, C. & Bjerrum, L. Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. Therapetic Advances and Drug Safety. 2014 Dec;5(6):229-41.
Le Minh, V. et al. In vitro activity of colistin in antimicrobial combination against carbapenem-resistant acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam. Journal of Medical Microbiology. 2015 Oct;64(10):1162-1169.
Mao, T., Hai, H., Duan, G. & Yang, H. Patterns of drug-resistant bacteria in a general hospital, China, 2011-2016. Polish Journal Microbiolgy. 68, 225–232.
Biedenbach, D. J. et al. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam. Clinical Therapeutics. 38, 2098–2105 (2016).
Kiratisin, P. et al. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: Results of Asia-Pacific surveillance from the COMPACT II study. International Journal of Antimicrobial Agents. 2012 Apr;39(4):311-6
Nhu, N. T. K. et al. Emergence of carbapenem-resistant Acinetobacter baumanniias the major cause of ventilatorassociated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. Journal of. Medical Microbiology. 2014 Oct;63(Pt 10):1386-1394.
Oliphant, C. M. & Eroschenko, K. Antibiotic Resistance, Part 2: Gram-negative Pathogens. Journal Nurse Practice. 2015;Jan;11, 79–86.
Jubeh, B., Breijyeh, Z. & Karaman, R. Resistance of gram-positive bacteria to current antibacterial agents and overcoming approaches. Molecules. 2020 Jun 23;25(12):2888
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. V. Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology. 2015;13, 42–51.
Eichenberger, E. M. & Thaden, J. T. Epidemiology and mechanisms of resistance of extensively drug resistant gram-negative bacteria. Antibiotics. 2019 Apr 6;8(2):37
Kapoor, G., Saigal, S., & Elongavan, A. Action and resistance mechanisms of antibiotics: A guide for clinicians. Journal of Anaesthesiology and Clinical Pharmacology. 2017; Jul-Sep;33(3):300-305.
Rice, L. B. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clinic. Procceding. 2012;87,198–208.
Kim, Y. J. et al. Risk factors for mortality in patients with carbapenem-resistant acinetobacter baumannii bacteremia: Impact of appropriate antimicrobial therapy. Journal of Korean Medical Science. 2012;2;(7),471–475.
Salahuddin, P., Kumar, A. & Khan, A. U. Structure, Function of Serine and Metallo-β-lactamases and their Inhibitors. Current Protein and Peptide Science. 2018;19(2):130-144.
Nordmann, P. & Poirel, L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clinical Infectious Diseases. 2019 Nov 13;69(Suppl 7):S521-S528.
Rollauer, S. E., Sooreshjani, M. A., Noinaj, N. & Buchanan, S. K. Outer membrane protein biogenesis in Gram-negative bacteria. Philosophical Transactions of the Royal Society Biological Sciences. 2015 Oct 5;370(1679):20150023.
de Maio Carrilho, C. M. D. et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. British Medical Council Infection Diseases. 2016; Nov 3;16(1):629.
Choe, Y. J., Lee, H. J. & Choi, E. H. Risk factors for mortality in children with acinetobacter baumannii bacteremia in South Korea: The role of carbapenem resistance. Microbial Drug Resistance. 2019;Oct;25(8):1210-1218
Sahbudak Bal, Z. et al. The prospective evaluation of risk factors and clinical influence of carbapenem resistance in children with gram-negative bacteria infection. American Journal of Infection. Control. 2018 Feb;46(2):147-153.
Liu, W. Da, Shih, M. C., Chuang, Y. C., Wang, J. T. & Sheng, W. H. Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia. Journal of Microbiology Immunology and Infection. 2019;52,788–795.
Inchai, J. et al. Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand. Journal of Infection and Chemotherapy. 2015;21, 570–574.
Čiginskienė, A., Dambrauskienė, A., Rello, J. & Adukauskienė, D. Ventilator-associated pneumonia due to drug-resistant acinetobacter baumannii: Risk factors and mortality relation with resistance profiles, and independent predictors of in-hospital mortality. Medicina. 2019;Feb;13;55(2):49.
Zheng, Y. L. et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. American Journal of. Infection Control. 2013;Jul;41(7):e59-63 41.
Luyt, C. E. et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrobial Agents and Chemotherapy. 2014;58(3):1372-80.
Kim, T. et al. Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: A multicenter study in Korea. Diagnostic Microbiology Infection Diseases. 2014;Apr;78(4):457-61.
Seligman, R. et al. Risk factors for infection with multidrug-resistant bacteria in non-ventilated patients with hospital-acquired pneumonia. Journal Brasileiro de Pneumologia. 2013;39(3),339–348.
Sieniawski, K., Kaczka, K., Rucinska, M., Gagis, L. & Pomorski, L. Acinetobacter baumannii nosocomial infections. Polish Journal of Surgery. 2013;Sep;85(9):483-90.
Mehrad, B., Clark, N. M., Zhanel, G. G. & Lynch, J. P. Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest. 2015 May;147(5):1413-1421.
Lahoorpour, F., Delpisheh, A. & Afkhamzadeh, A. Risk factors for acquisition of ventilator-associated pneumonia in adult intensive care units. Pakistan Journal of Medical Science. 2013 Sep;29(5):1105-7.
Wu, D., Wu, C., Zhang, S. & Zhong, Y. Risk factors of ventilator-associated pneumonia in critically III patients. Frontiers in Pharmacology. 2019;May 9;10:482.
Wang, Z., Qin, R. R., Huang, L. & Sun, L. Y. Risk Factors for Carbapenem-resistant Klebsiella pneumoniae Infection and Mortality of Klebsiella pneumoniae Infection. Chinese Medical Journal. 2018;Jan 5; 131(1): 56–62.
Van Duin, D. et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases. 2018 Jan 15; 66(2): 163–171.
Hosoglu, S., Arslan, E., Aslan, E. & Deveci, Ö. Use of carbapenems and glycopepdides is significant risk for multidrug resistant Acinetobacter baumannii infections. Journal of Infection in Developing Countries. 2018;12, 67–72.
Kalil, A. C. et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical. Infectious Diseases. 2016;63,e61–e111.
Jiao, Y. et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: A retrospective study. Pathogens Global Health. 2015;109, 68–74.
Li, J., Li, Y., Song, N. & Chen, Y. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: A meta-analysis. Journal of Global Antimicrobial Resistance. 2020;21, 306–313.
Mietto, C., Pinciroli, R., Patel, N. & Berra, L. Ventilator associated pneumonia: Evolving definitions and preventive strategies. Respiratory Care. 2013;58, 990–1003.
Matthew E. Falagas, Giannoula S. Tansarli, Drosos E. Karageorgopoulos & and Konstantinos Z. Vardakas. Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections. Emerging Infectious Diseases Journal. 2014;20, 1170–1175.
Ny, P., Nieberg, P. & Wong-Beringer, A. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections. American Journal of Infection Control. 2015;Oct 1;43(10):1076-80
Zilberberg, M. D., Nathanson, B. H., Sulham, K., Fan, W. & Shorr, A. F. A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study. Chest. 2019 Jun;155(6):1119-1130
Xia, J. et al. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. International Journal of Infectious Diseases. 2014;23, 90–93.
Cheng, A. et al. Excess Mortality Associated with Colistin-Tigecycline Compared with Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study. Critical Care Medicine. 2015;43, 1194–1204.
Ku, Y. H. et al. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance. Journal of Microbiology, Immunology and Infection. 2017;50, 931–939.
Paul, M. et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases. 2018 Apr;18(4):391-400.
Cisneros, J. M. et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Critical Care. 2019 Nov 28;23(1):383.
Yu, L. et al. Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro. Frontiers Cellular and Infection Microbiology. 2019; Dec 10;9:422.
Centers for Disease and Prevention. Healthcare Infection Control Practices Advisory Committee (HICPAC): Guidelines for Environmental Infection Control in Health-Care Facilities. U.S. Department of Health and Human Services for Diseases and Control Prevention. Atlanta, GA 30329 1–235 (2019).
Kementrian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Infeksi di Fasilitas Pelayanan Kesehatan. (2017).
DOI: https://doi.org/10.15416/pcpr.v6i1.32282
Refbacks
- There are currently no refbacks.
